Brought to you by 
Cannasat and IntelGenx co-develop a mood disorder candidate
17 Jun 2022
Executive Summary
Cannasat Therapeutics (medicinal cannabis) and drug delivery pharma IntelGenx have agreed to combine their delivery technologies to co-develop the cannabinoid candidate CAT320 for mood disorders such as anxiety and depression.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D (No Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cannasat and IntelGenx co-develop a mood disorder candidate
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice